Martin Currie LTD Zai Lab LTD Transaction History

Martin Currie LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$30.47 - $37.65 $267,953 - $331,094	-8,794 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$25.73 - $35.79 $14,846 - $20,650	-577 Reduced 6.16%	8,794 $307,000
Q1 2019 May 15, 2019	SELL	$21.71 - $31.54 $16,890 - $24,538	-778 Reduced 7.67%	9,371 $277,000
Q4 2018 Feb 14, 2019	BUY	$14.95 - $24.72 $23,157 - $38,291	1,549 Added 18.01%	10,149 $236,000
Q3 2018 Nov 14, 2018	SELL	$17.8 - $25.35 $35,600 - $50,700	-2,000 Reduced 18.87%	8,600 $168,000
Q2 2018 Aug 14, 2018	SELL	$18.0 - $25.01 $14,400 - $20,008	-800 Reduced 7.02%	10,600 $246,000
Q1 2018 May 15, 2018	BUY	$20.05 - $26.96 $60,150 - $80,880	3,000 Added 35.71%	11,400 $243,000
Q4 2017 Feb 14, 2018	BUY	$21.23 - $34.09 $178,332 - $286,356	8,400	8,400 $178,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.75B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Martin Currie LTD, based on Form 13F filings with the SEC.

Stay updated on Martin Currie LTD with notifications on news.